FDA advisers back Grail's Galleri cancer blood test 7-2, but split 6-4 on whether it works

A Food and Drug Administration advisory panel on Wednesday voted 7-2, with one abstention, that the benefits of Grail's Galleri blood test outweigh its risks for screening adults aged 50 and older for multiple cancers. The panel voted 10-0 that the test is safe and 6-4 that it is effective, according to Grail's announcement and STAT. The FDA is not bound by the vote and is expected to decide in the coming months.

It is the first time a federal advisory group has backed a multi-cancer blood test, the Associated Press reported. Grail filed its premarket approval application on Jan. 29, 2026; the test has had Breakthrough Device status since 2018.

The number the headline leaves out

"Endorses" is accurate, but the effectiveness vote was close, and the data explain why. In Grail's main study of about 140,000 older adults, the test detected about one-third of the cancers diagnosed over the following year, the AP reported. About two-thirds of people who got a "cancer signal detected" result were later confirmed to have cancer.

Put simply, for every three cancers found in that group within a year, Galleri flagged one. For every three positive results, two were real cancers and one was a false alarm needing follow-up. The FDA's chief reviewer stressed the first number: the test missed two of every three cancers diagnosed in the next year. The panel also declined to endorse the phrase "early detection," the AP said, because the test was less accurate at finding early-stage tumors. Grail did not present data showing fewer cancer deaths, which would take years of follow-up.

Grail's case is that Galleri looks for a signal across more than 50 cancers, many with no screening today, such as liver and ovarian cancer. The company says that in its studies it found four to seven times more cancers than standard screening alone. The panel said the test should be used on top of existing screening, never instead of it, and that a negative result is not an all-clear.

What approval would change

People in the U.S. can already buy Galleri, usually paying $700 or more in cash, according to the AP. The commercial prize is coverage: FDA approval would likely open the door to Medicare and private insurers. That is the step that turns a cash test into a volume business. It also matters to employers that pay for health plans, because a covered test that triggers follow-up scans on one positive in three adds costs further down the line.

What traders already priced in

Much of the move came before the vote. Grail shares jumped 34% on Monday, Sept. 21, to $107.97 from $80.77 after FDA briefing documents for the meeting were posted, Nasdaq data show. Tuesday's close was $108.52, and Nasdaq showed trades around $109.40 after hours Wednesday on thin volume. The market value is about $4.9 billion and the 52-week range is $41.50 to $118.84. The next catalyst is the FDA's own decision, which can differ from the panel, plus any post-approval study requirements the agency attaches.

Sources: GRAIL press release; Associated Press; STAT; FDA meeting page; Nasdaq quotes. This is market information, not investment or medical advice.